Epidemiology of acute upper gastrointestinal bleeding

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 2, 2008, Pages 209-224

  van Leerdam, M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

peptic ulcer bleeding; upper gastrointestinal bleeding; variceal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; SOMATOSTATIN; TERLIPRESSIN;

ACUTE DISEASE; ADENOMA; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SURGERY; GASTROSCOPY; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MONOTHERAPY; MORTALITY; NONHUMAN; PEPTIC ULCER BLEEDING; POPULATION RESEARCH; RECURRENT DISEASE; RISK FACTOR; TREND STUDY; UPPER GASTROINTESTINAL BLEEDING; VASCULAR DISEASE; VEIN LIGATION;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGITIS; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; PEPTIC ULCER HEMORRHAGE; RECURRENCE; RISK FACTORS; UPPER GASTROINTESTINAL TRACT;

EID: 40649127716     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.10.011     Document Type: Article

References (72)

1. Brown R.C., and Langman M.J. Proceedings: hospital admission for peptic ulcer and acute gastrointestinal bleeding in the United Kingdom 1958-70. Gut 15 4 (1974) 335
2. Elashoff J.D., and Grossman M.I. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978. Gastroenterology 78 2 (1980) 280-285
3. Primatesta P., Goldacre M.J., and Seagroatt V. Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol 23 6 (1994) 1206-1217
4. Jibril J.A., Redpath A., and Macintyre I.M. Changing pattern of admission and operation for duodenal ulcer in Scotland. Br J Surg 81 1 (1994) 87-89
5. Lewis J.D., Bilker W.B., Brensinger C., et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 97 10 (2002) 2540-2549
6. Kang J.Y., Tinto A., Higham J., et al. Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther 16 6 (2002) 1067-1074
7. Bardhan K.D., Cust G., Hinchliffe R.F., et al. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg 76 3 (1989) 230-236
8. Thors H., Svanes C., and Thjodleifsson B. Trends in peptic ulcer morbidity and mortality in Iceland. J Clin Epidemiol 55 7 (2002) 681-686
9. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 132 7 (2007) 2320-2327
10. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 102 5 (2007) 1101-1107
11. Kurata J.H., Honda G.D., and Frankl H. Hospitalization and mortality rates for peptic ulcers: a comparison of a large health maintenance organization and United States data. Gastroenterology 83 5 (1982) 1008-1016
12. Kurata J.H., and Corboy E.D. Current peptic ulcer time trends. An epidemiological profile. J Clin Gastroenterol 10 3 (1988) 259-268
13. Tilvis R.S., Vuoristo M., and Varis K. Changed profile of peptic ulcer disease in hospital patients during 1969-1984 in Finland. Scand J Gastroenterol 22 10 (1987) 1238-1244
14. Blatchford O., Davidson L.A., Murray W.R., et al. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 315 7107 (1997) 510-514
15. van Leerdam M.E., Vreeburg E.M., Rauws E.A., et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 98 7 (2003) 1494-1499
16. Yavorski R.T., Wong R.K., Maydonovitch C., et al. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. Am J Gastroenterol 90 4 (1995) 568-573
17. Vreeburg E.M., Snel P., de Bruijne J.W., et al. Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol 92 2 (1997) 236-243
18. Longstreth G.F. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 90 2 (1995) 206-210
19. Czernichow P., Hochain P., Nousbaum J.B., et al. Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas. Eur J Gastroenterol Hepatol 12 2 (2000) 175-181
20. Paspatis G.A., Matrella E., Kapsoritakis A., et al. An epidemiological study of acute upper gastrointestinal bleeding in Crete, Greece. Eur J Gastroenterol Hepatol 12 11 (2000) 1215-1220
21. Lau J.Y., Sung J.J., Lee K.K., et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 343 5 (2000) 310-316
22. Kubba A.K., Murphy W., and Palmer K.R. Endoscopic injection for bleeding peptic ulcer: a comparison of adrenaline alone with adrenaline plus human thrombin. Gastroenterology 111 3 (1996) 623-628
23. Thomopoulos K.C., Vagenas K.A., Vagianos C.E., et al. Changes in aetiology and clinical outcome of acute upper gastrointestinal bleeding during the last 15 years. Eur J Gastroenterol Hepatol 16 2 (2004) 177-182
24. Barkun A., Sabbah S., Enns R., et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 99 7 (2004) 1238-1246
25. Targownik L.E., and Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin Gastroenterol Hepatol 4 12 (2006) 1459-1466
26. Rockall T.A., Logan R.F., Devlin H.B., et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 311 6999 (1995) 222-226
27. Rockall T.A., Logan R.F., Devlin H.B., et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 346 8971 (1995) 346-350
28. Rockall T.A., Logan R.F., Devlin H.B., et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 38 3 (1996) 316-321
29. Brullet E., Campo R., Calvet X., et al. Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer. Gut 39 2 (1996) 155-158
30. Klebl F.H., Bregenzer N., Schofer L., et al. Comparison of inpatient and outpatient upper gastrointestinal haemorrhage. Int J Colorectal Dis 20 4 (2005) 368-375
31. Sandel M.H., Kolkman J.J., Kuipers E.J., et al. Nonvariceal upper gastrointestinal bleeding: differences in outcome for patients admitted to internal medicine and gastroenterological services. Am J Gastroenterol 95 9 (2000) 2357-2362
32. Alexander S., Nathan D.M., and Korman M.G. Outcome of peptic ulcer bleeding. Clin Gastroenterol Hepatol 4 5 (2006) 661-662
33. Dursun M., Yilmaz S., Yukselen V., et al. Analysis of 1242 cases with upper gastrointestinal system bleeding in Southeastern Turkey: a different etiologic spectrum. Hepatogastroenterology 52 65 (2005) 1456-1458
34. del Olmo J.A., Pena A., Serra M.A., et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 32 1 (2000) 19-24
35. Afessa B., and Kubilis P.S. Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 95 2 (2000) 484-489
36. Lecleire S., Di Fiore F., Merle V., et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol 39 4 (2005) 321-327
37. Chassaignon C., Letoumelin P., and Pateron D. Upper gastrointestinal haemorrhage in Emergency Departments in France: causes and management. Eur J Emerg Med 10 4 (2003) 290-295
38. Di Fiore F., Lecleire S., Merle V., et al. Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and practices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 17 6 (2005) 641-647
39. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 5 (2000) 846-852
40. Ramsoekh D., van Leerdam M.E., Rauws E.A., et al. Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use, and Helicobacter pylori infection. Clin Gastroenterol Hepatol 3 9 (2005) 859-864
41. Lim C.H., Vani D., Shah S.G., et al. The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. Endoscopy 38 6 (2006) 581-585
42. Ohmann C., Imhof M., Ruppert C., et al. Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 40 8 (2005) 914-920
43. Mamdani M., Warren L., Kopp A., et al. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ 175 12 (2006) 1535-1538
44. Post P.N., Kuipers E.J., and Meijer G.A. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 23 11 (2006) 1587-1593
45. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 9300 (2002) 14-22
46. van Leerdam M.E., and Tytgat G.N. Review article: Helicobacter pylori infection in peptic ulcer haemorrhage. Aliment Pharmacol Ther 16 Suppl.1 (2002) 66-78
47. Laine L., and Peterson W.L. Bleeding peptic ulcer. N Engl J Med 331 11 (1994) 717-727
48. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 9300 (2002) 9-13
49. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 24 (1999) 1888-1899
50. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 4 (1995) 241-249
51. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 10 (1991) 787-796
52. Hernandez-Diaz S., and Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160 14 (2000) 2093-2099
53. Garcia Rodriguez L.A., and Barreales T.L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 2 (2007) 498-506
54. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 21 (2000) 1520-1528 2
55. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 9435 (2004) 665-674
56. Lanas A., Baron J.A., Sandler R.S., et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132 2 (2007) 490-497
57. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 9573 (2007) 1621-1626
58. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 13 (2006) 1633-1644
59. Curfman G.D., Morrissey S., and Drazen J.M. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,". N Engl J Med 343 (2000) 1520-1528 N Engl J Med 2005; 353(26): 2813-2814
60. Kuipers E.J., Thijs J.C., and Festen H.P. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 9 Suppl 2 (1995) 59-69
61. Rauws E.J., and Tytgat G.N. Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin Gastroenterol 9 3 (1995) 529-547
62. Lee J.M., Breslin N.P., Fallon C., et al. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 95 5 (2000) 1166-1170
63. Wu C.Y., Poon S.K., Chen G.H., et al. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scand J Gastroenterol 34 3 (1999) 234-237
64. Aalykke C., Lauritsen J.M., Hallas J., et al. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 116 6 (1999) 1305-1309
65. Graham D.Y., Hepps K.S., Ramirez F.C., et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28 11 (1993) 939-942
66. Lai K.C., Hui W.M., Wong W.M., et al. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage-a long-term randomized, controlled study. Am J Gastroenterol 95 9 (2000) 2225-2232
67. Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 94 7 (1999) 1834-1840
68. Chan H.L., Wu J.C., Chan F.K., et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc 53 4 (2001) 438-442
69. Sugiyama T., Nishikawa K., Komatsu Y., et al. Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers?. Dig Dis Sci 46 2 (2001) 307-310
70. Nishikawa K., Sugiyama T., Kato M., et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 12 6 (2000) 635-640
71. Gisbert J.P., Gonzalez L., de Pedro A., et al. Helicobacter pylori and bleeding duodenal ulcer: prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 36 7 (2001) 717-724
72. Malfertheiner P., Megraud F., and O'Morain C. Current concepts in the management of H. pylori infection- The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180